|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2009-9-2
|
|
pubmed:abstractText |
The biological effect of interleukin-6 (IL-6) signaling in oral squamous cell carcinoma (OSCC) and whether IL-6 receptor (IL-6R)-mediated signaling can be a therapeutic target for OSCC are unclear. The aim of this study was to investigate the effects of inhibition of IL-6R-mediated signaling on OSCC progression and to evaluate the availability of tocilizumab, a humanized antihuman IL-6R antibody, as a therapeutic agent for OSCC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD31,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/STAT3 Transcription Factor,
http://linkedlifedata.com/resource/pubmed/chemical/STAT3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/tocilizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AndoYukioY,
pubmed-author:EndoMotoyoshiM,
pubmed-author:HirakiAkimitsuA,
pubmed-author:IbusukiMutsukoM,
pubmed-author:JonoHirofumiH,
pubmed-author:KudoMareinaM,
pubmed-author:NakayamaHidekiH,
pubmed-author:OikeYuichiY,
pubmed-author:OtaKazutoshiK,
pubmed-author:OtaTomokoT,
pubmed-author:ShinoharaMasanoriM,
pubmed-author:ShinrikiSatoruS,
pubmed-author:UedaMitsuharuM,
pubmed-author:YoshitakeYoshihiroY
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5426-34
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19706815-Aged,
pubmed-meshheading:19706815-Angiogenesis Inhibitors,
pubmed-meshheading:19706815-Animals,
pubmed-meshheading:19706815-Antibodies, Monoclonal,
pubmed-meshheading:19706815-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19706815-Antigens, CD31,
pubmed-meshheading:19706815-Carcinoma, Squamous Cell,
pubmed-meshheading:19706815-Cell Line, Tumor,
pubmed-meshheading:19706815-Female,
pubmed-meshheading:19706815-Humans,
pubmed-meshheading:19706815-Interleukin-6,
pubmed-meshheading:19706815-Ki-67 Antigen,
pubmed-meshheading:19706815-Male,
pubmed-meshheading:19706815-Mice,
pubmed-meshheading:19706815-Mice, SCID,
pubmed-meshheading:19706815-Middle Aged,
pubmed-meshheading:19706815-Mouth Neoplasms,
pubmed-meshheading:19706815-Neovascularization, Pathologic,
pubmed-meshheading:19706815-RNA, Small Interfering,
pubmed-meshheading:19706815-Receptors, Interleukin-6,
pubmed-meshheading:19706815-STAT3 Transcription Factor,
pubmed-meshheading:19706815-Vascular Endothelial Growth Factor A,
pubmed-meshheading:19706815-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
|
|
pubmed:affiliation |
Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
